FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.

doi:10.1038/s41375-019-0694-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.

Leukemia - 1 Mar 2020

Antar Ahmad I, Otrock Zaher K, Jabbour Elias, Mohty Mohamad, Bazarbachi Ali

Abstract excerpt

The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately one third of patients with acute myeloid leukemia (AML), either by internal tandem duplications (FLT3-ITD), or by a point mutation mainly involving the tyrosine kinase domain (FLT3-TKD). Patients with FLT3-ITD have a high risk...

Topics

Aniline Compounds
Antineoplastic Agents
Benzimidazoles
Benzothiazoles
Carbazoles
DNA Methylation
Enzyme Inhibitors
Furans
Humans
Leukemia, Myeloid, Acute
Mutation
Neoplasm Recurrence, Local
Phenylurea Compounds
Piperidines
Prognosis
Pyrazines
Randomized Controlled Trials as Topic
Sorafenib

Source

Open in PubMed

Identifiers

PMID: 31919472
DOI: 10.1038/s41375-019-0694-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-31919472-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics